What Is the Best Peptide to Add to TRT? (TRT Q&As)
Timeline
Timestamp
Topic
02:10
What would be the best peptide to add to a TRT protocol?
The member is particularly interested in peptides promoted for reducing abdominal fat. Dr. O’Connor discusses tesamorelin, CJC-1295, ipamorelin, BPC-157 and other compounds, but emphasizes the limited evidence behind many peptide claims and recommends focusing on the ABCDs™, diet, training, and proven health measures rather than assuming a peptide is necessary.
The member is particularly interested in peptides promoted for reducing abdominal fat. Dr. O’Connor discusses tesamorelin, CJC-1295, ipamorelin, BPC-157 and other compounds, but emphasizes the limited evidence behind many peptide claims and recommends focusing on the ABCDs™, diet, training, and proven health measures rather than assuming a peptide is necessary.
21:20
Could switching abruptly from testosterone propionate to cypionate and lowering my dose be why I feel terrible?
The member describes moving rapidly from high-dose testosterone and Primobolan to prescription-dose testosterone cypionate and developing symptoms he associates with crashed estradiol. Dr. O’Connor explains that the large reduction in total androgen exposure may be more important than the ester change itself and discusses a gradual harm-reduction approach rather than abruptly dropping from supraphysiologic dosing.
The member describes moving rapidly from high-dose testosterone and Primobolan to prescription-dose testosterone cypionate and developing symptoms he associates with crashed estradiol. Dr. O’Connor explains that the large reduction in total androgen exposure may be more important than the ester change itself and discusses a gradual harm-reduction approach rather than abruptly dropping from supraphysiologic dosing.
40:30
Could testosterone, Primobolan, or other PEDs be contributing to my rapidly developing peripheral neuropathy?
A 56-year-old man describes new tingling and neurologic symptoms in his hands and feet after increasing testosterone and experimenting with several PEDs. Dr. O’Connor emphasizes that progressive neurologic deficits require proper neurologic and spinal evaluation rather than assuming the symptoms are simply a steroid side effect.
A 56-year-old man describes new tingling and neurologic symptoms in his hands and feet after increasing testosterone and experimenting with several PEDs. Dr. O’Connor emphasizes that progressive neurologic deficits require proper neurologic and spinal evaluation rather than assuming the symptoms are simply a steroid side effect.
55:00
Should I get a venogram for suspected nutcracker syndrome before starting TRT?
A 27-year-old man with bilateral varicoceles, low testosterone, flank pain, and suspected renal vein compression asks whether vascular testing should come before testosterone. Dr. O’Connor favors further evaluation by vascular, urology, and kidney specialists so the underlying problem is better understood before committing to long-term TRT.
A 27-year-old man with bilateral varicoceles, low testosterone, flank pain, and suspected renal vein compression asks whether vascular testing should come before testosterone. Dr. O’Connor favors further evaluation by vascular, urology, and kidney specialists so the underlying problem is better understood before committing to long-term TRT.
66:40
If I start TRT with suspected nutcracker syndrome, should I also take aspirin, nattokinase, or serrapeptase to reduce blood-clot risk?
Dr. O’Connor explains that aspirin primarily acts as an antiplatelet drug and is different from anticoagulants used for venous clot prevention. He does not recommend casually adding blood-thinning agents and says the member needs specialist assessment of his actual thrombosis and bleeding risks.
Dr. O’Connor explains that aspirin primarily acts as an antiplatelet drug and is different from anticoagulants used for venous clot prevention. He does not recommend casually adding blood-thinning agents and says the member needs specialist assessment of his actual thrombosis and bleeding risks.
Video Summary
This session addresses a range of questions that come up in real-world hormone and metabolic care. Rather than treating any single number as definitive, the discussion emphasizes decision-making that integrates symptoms, history, and repeatable trends. Viewers get a clear sense of how clinicians prioritize stability and follow-up when uncertainty is high.
Several segments focus on how and when to adjust a plan, including dosing choices, monitoring cadence, and symptom tracking. The conversation highlights common misinterpretations that lead to unnecessary changes, and it explains what would justify reassessment. Practical framing is provided so patients can bring better questions to follow-up visits.
Risk and prevention themes also appear throughout, including cardiometabolic markers and long-term health planning. The session reinforces that individualized care depends on context, goals, and tolerability, not rigid rules. Overall, the episode provides a structured way to think about next steps without losing sight of long-term outcomes.
Drug Callouts
Drug
Description
Testosterone
Testosterone is an androgen hormone that supports sexual function, red blood cell production, bone density, and muscle mass. The Q&A touches on testosterone in the context of monitoring goals, symptom reports, and risk tradeoffs discussed during the session.
Tadalafil
Tadalafil is a phosphodiesterase-5 inhibitor used to treat erectile dysfunction and sometimes benign prostatic hyperplasia by improving blood flow. Tadalafil is mentioned alongside related labs and symptoms, framing how clinicians think about decisions over time rather than single moments.
Condition Callouts
Condition
Description
Diabetes
Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia due to impaired insulin secretion, insulin action, or both. The conversation references diabetes while weighing practical next steps, follow-up timing, and what would trigger reconsideration.
Hypertension
Hypertension is persistently elevated arterial blood pressure that increases the risk of cardiovascular, cerebrovascular, and renal disease. The conversation references hypertension while weighing practical next steps, follow-up timing, and what would trigger reconsideration.
Polycythemia
Polycythemia is an increased concentration of red blood cells, which can raise blood viscosity and thrombotic risk. Polycythemia is mentioned alongside related labs and symptoms, framing how clinicians think about decisions over time rather than single moments.
Key Takeaways
- Dose changes should be trend-driven and anchored to symptom patterns rather than isolated results.
- Administration consistency reduces variability and supports clearer interpretation of response.
- Monitoring works best when it is matched to specific clinical decisions and safety thresholds.
- Symptoms can lag behind lab changes, so timelines should be set realistically.
- Long-term follow-up structure prevents overreaction and improves outcomes.